Dashboard
Manage Tickers

GILD


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

gileads-one-pill-hiv-treatment-shows-promise-in-late-stage-trial
Gilead's One-Pill HIV Treatment Shows Prom...
11/13/2025 18:55:41

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy a...

needham-maintains-buy-on-gilead-sciences-raises-price-target-to-140
Needham Maintains Buy on Gilead Sciences, ...
11/13/2025 18:11:32

Needham analyst Joseph Stringer maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $133 to ...

this-gilead-sciences-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday
This Gilead Sciences Analyst Begins Covera...
11/13/2025 13:45:16

gilead-sciences-releases-topline-results-from-phase-3-artistry-1-trial-showing-that-once-daily-single-tablet-regimen-of-bictegravir-75-mglenacapavir-50-mg-is-non-inferior-to-multi-tablet-antiretroviral-regimens-in-virologically-suppressed-adults-with-hiv
Gilead Sciences Releases Topline Results F...
11/13/2025 13:43:09

Gilead Sciences, Inc. (NASDAQ:GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The open-label ...

scotiabank-initiates-coverage-on-gilead-sciences-with-sector-outperform-rating-announces-price-target-of-140
Scotiabank Initiates Coverage On Gilead Sc...
11/13/2025 12:24:06

Scotiabank analyst Louis Chen initiates coverage on Gilead Sciences (NASDAQ:GILD) with a Sector Outperform rating and announ...

gilead-cfo-says-medicare-reform-is-about-900m-headwind-for-hiv-business-12b-headwind-for-business-overall
Gilead CFO Says Medicare Reform Is About $...
11/10/2025 16:12:57

- Reuters Citing Conf Call

gilead-cfo-says-hiv-business-is-now-projected-to-grow-5-this-year
Gilead CFO Says HIV Business Is Now Projec...
11/10/2025 16:11:23

- Reuters Citing Conf Call

in-oct-gilead-sciences-reached-settlement-with-a-tax-authority-related-to-a-prior-year-legal-entity-restructuring--sees-450m-of-income-tax-benefit-and-a-corresponding-530m-reduction-in-unrecognized-tax-benefits-in-quarter-ending-dec-31
In Oct, Gilead Sciences Reached Settlement...
11/07/2025 21:26:50

-SEC Filing

gileads-trodelvy-misses-main-goal-in-breast-cancer-study-but-shows-early-survival-trend
Gilead's Trodelvy Misses Main Goal In Brea...
11/07/2025 15:10:32

Gilead's Trodelvy missed a key goal in breast cancer, while Livdelzi showed durable efficacy and safety in long-term liver ...

gilead-says-phase-3-ascent-07-study-of-trodelvy-did-not-meet-primary-endpoint-of-progression-free-survival
Gilead Says Phase 3 ASCENT-07 Study Of Tro...
11/07/2025 13:31:38

gilead-announces-long-term-data-showing-sustained-efficacy-in-primary-biliary-cholangitis
Gilead Announces Long-Term Data Showing Su...
11/07/2025 13:04:22

Core News & Articles
10 Health Care Stocks Whale Activity In To...
11/05/2025 17:35:20

truist-securities-reiterates-buy-on-gilead-sciences-raises-price-target-to-145
Truist Securities Reiterates Buy on Gilead...
11/03/2025 15:23:56

Truist Securities analyst Asthika Goonewardene reiterates Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price targ...

gilead-sciences-and-kite-to-present-21-abstracts-including-5-oral-presentations-showcasing-kites-continued-progress-in-transforming-blood-cancer-care-and-expanding-reach-and-impact-of-car-t-cell-therapy-at-ash-2025
Gilead Sciences And Kite To Present 21 Abs...
11/03/2025 14:21:20

– Updated Results from Phase 2 Pivotal iMMagine-1 Study of Anito-cel for Relapsed/Refractory Multiple Myeloma to be Presented O...

wells-fargo-maintains-overweight-on-gilead-sciences-raises-price-target-to-145
Wells Fargo Maintains Overweight on Gilead...
10/31/2025 21:12:51

Wells Fargo analyst Mohit Bansal maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from ...

jp-morgan-maintains-overweight-on-gilead-sciences-raises-price-target-to-150
JP Morgan Maintains Overweight on Gilead S...
10/31/2025 18:36:06

JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $1...

gileads-hiv-drugs-power-earnings-beat-company-eyes-multiple-launches-by-2026
Gilead's HIV Drugs Power Earnings Beat, Co...
10/31/2025 17:41:12

Gilead beats estimates, raises 2025 guidance, driven by strong HIV and liver drug sales and multiple launches planned for 2026.

nasdaq-100-rebounds-amazon-jumps-10-on-strong-earnings-whats-moving-markets-friday
Nasdaq 100 Rebounds, Amazon Jumps 10% On S...
10/31/2025 17:26:36

Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap gi...

rbc-capital-maintains-sector-perform-on-gilead-sciences-raises-price-target-to-105
RBC Capital Maintains Sector Perform on Gi...
10/31/2025 14:57:23

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target...

cantor-fitzgerald-reiterates-overweight-on-gilead-sciences-maintains-135-price-target
Cantor Fitzgerald Reiterates Overweight on...
10/31/2025 13:36:40

Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $135 price t...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION